Background: Short/branched-chain acyl-CoA dehydrogenase (SBCAD) deficiency is a rare inborn error of metabolism with uncertain clinical significance. As it leads to C5-carnitine (i.e. isovalerylcarnitine, 2methylbutyrilcar-nitine, or pivaloylcarnitine) elevation, SBCAD deficiency is detectable at newborn screening, requiring differential diagnosis from isovaleric acidemia and pivalic acid administration. Increased urinary excretion of 2-methylbutyrylglycine (2MBG) is the hallmark of SBCAD deficiency. Methods: We report two cases of SBCAD deficiency and provide a review of the available literature on this condition. Results: Two siblings newly diagnosed with SBCAD deficiency are reported. Newborn screening allowed the early diagnosis in the second-born (C5 = 0.5 μmol/L, normal 0.05-0.3 μmol/L) and addressed selective screening in the 5-year asymptomatic brother (C5 = 1.9 μmol/L). Both patients showed increased urinary excretion of 2MBG and two mutations in the ACADSB gene (c.443C>T/c.1145C>T). Currently, both the patients are asymptomatic. Longitudinal biochemical monitoring of the two patients while on treatment with carnitine (100 mg/kg/day) was provided. Based on our experience and the literature review (162 patients), SBCAD deficiency is symptomatic in about 10% of reported patients. Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure to thrive. On longitudinal followup, epilepsy, developmental delay, microcephaly, and autism can develop. Acute metabolic decompensation due to catabolic stressors can occur, as observed in one newly reported patient. Fifteen mutations in the ACADSB
Introduction
Short/branched-chain acyl-CoA dehydrogenase (SBCAD, also known as 2-methylbutyryl-CoA dehydrogenase, EC 1.3.99.12) is a homotetrameric mitochondrial enzyme catalyzing the third step of the isoleucine S-pathway -the conversion of (S)-2-methylbutyryl-CoA into tiglyl-CoA -and the first oxidative step of L-2-methylated short acyl-CoA compounds, being likely implicated in valproate metabolism [1, 2] . SBCAD deficiency (OMIM 600301/610006) was first described in 2000 [3, 4] . Biochemically, increased urinary excretion of 2-methylbutyrylglycine (2MBG) and elevated blood concentrations of 2-methylbutyrylcarnitine are the hallmarks of this disorder. The latter can be detected at newborn screening by acylcarnitine analysis as C5-carnitine (i.e. isovalerylcarnitine, 2methylbutyrilcarnitine, or pivaloylcarnitine) elevation, requiring differential diagnosis from isovalerylcarnitine (a marker of isovaleric acidemia) and pivaloylcarnitine (a component of several antibiotics).
The clinical significance of SBCAD deficiency is unclear. The first patients identified with 2-methylbutyrylglycinuria showed severe neurologic pictures at onset and developmental delay on long-term follow-up [3, 4] . On the other hand, SBCAD deficiency was diagnosed in asymptomatic adults as well, and neonatal screening studies revealed high prevalence of asymptomatic newborns, especially in the Hmong population [5] [6] [7] .
Here we review the clinical, biochemical, and molecular data of published cases of SBCAD deficiency. Furthermore, we report two new cases of SBCAD deficiency, expanding the clinical and molecular spectrum of this condition.
Patients and methods
PubMed was searched using the keywords short/branched chain acyl-CoA dehydrogenase, 2-methylbutyryl-CoA dehydrogenase, 2-methylbutyrylglycinuria, and the ACADSB gene. Patients whose data had been published were subdivided according to the occurrence of clinical symptoms. Data on diagnostic approach, biochemical characteristics (C5 and 2MBG), family descent, genotype, treatment, and the duration of follow-up were collected for all the patients. As for symptomatic patients, age at onset, clinical symptoms, and imaging studies were recorded. Additionally, two newly diagnosed patients with SBCAD deficiency were described. Informed consent was obtained for inclusion in the study. Newborn screening was performed using the NeoBase™ Non-derivatized MSMS kit (PerkinElmer, Inc., Waltham, MA, USA). Organic acids and molecular analyses were performed by gas chromatography-mass spectrometry and Sanger sequencing, respectively, as described elsewhere [8, 9] . Statistical analysis was performed using R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria). The Shapiro-Wilk test was used for testing the normality of data distribution. Differences between groups were established using Student's t-test or the Mann-Whitney U test [10] . Statistical significance for all calculations was considered achieved when the two-tailed p-value was less than 0.050. The study was conducted according to the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects.
Results

Case reports
The first diagnosed patient was detected at newborn screening performed at 3 days of life showing slight C5-carnitine elevation (0.5 μmol/L, normal range 0.05-0.3 μmol/L). Urinary organic acids showed increased excretion of 2MBG. Molecular analysis revealed a compound heterozygosity for the known pathogenic mutation c.443C>T (p.Thr148Ile) associated to the new variant c.1145C>T (p.Thr382Met). The functional effect of this new variant was predicted using a bioinformatics tool (PolyPhen-2), resulting in its high probability of protein damage (score: 1.000). Its minimal allele frequency resulted in ~1:50,000 in non-Finnish European individuals (based on GnomAD).
Investigations in her 5-year-old asymptomatic brother (who did not undergo expanded newborn screening) revealed overlapping biochemical (C5 = 1.9 μmol/L, increased urine 2MBG) and molecular features. Medical history of this patient revealed a life-threatening episode characterized by metabolic acidosis and coma during an acute febrile gastroenteritis that occurred at 3 years of age. After urgent hospitalization, glucosaline infusion rapidly corrected the clinical features and the biochemical picture.
Since the diagnosis of SBCAD deficiency, both patients were treated with carnitine (100 mg/kg/day). Additionally, instructions to avoid fasting and protein overloads and an emergency protocol for the management of intercurrent febrile illnesses were delivered to the parents. In both patients, uneventful clinical follow-up lasted until present (1 year). Longitudinal biochemical monitoring of blood C5-carnitine in the two patients while on treatment with carnitine is depicted in Figure 1 . Both patients showed steadily increasing urinary excretion of 2MBG while on treatment.
Clinical features of SBCAD deficiency
Symptomatic patients
Including this report, 13 symptomatic patients with SBCAD deficiency were reported (Table 1 ). Age at onset Gibson et al. [3] Madsen et al. [11] ranged from 3 days to 6 years. The main clinical symptoms at onset included seizures, developmental delay, hypotonia, and failure to thrive [3] [4] [5] [11] [12] [13] [14] [15] . Neonatal-onset SBCAD deficiency was reported in four patients (31%), all sharing seizures as the common feature (one newborn was concomitantly affected by non-ketotic hyperglycinemia). Infantile-onset (within the first year) was reported in five patients (38%) with SBCAD deficiency, characterized by variable association of seizures, developmental delay, hypotonia, and failure to thrive. Four patients (31%) presented clinical symptoms after the first year, generally showing hypotonia and neuromotor delay, with the exception of one patient presenting with acute metabolic decompensation during febrile gastroenteritis (newly described case) followed by normal clinical outcome.
On longitudinal follow-up, epilepsy, developmental delay, and microcephaly were the most common features; autism was reported in one patient.
Asymptomatic patients
One-hundred and forty-nine asymptomatic patients with SBCAD deficiency were reported ( Table 2 ). All but seven patients (95%) were detected at newborn screening [5-7, 15, 13, 16] . One-hundred and twenty-six patients were of Hmong descent (85%), sharing homozygosity for the c.1165A>G mutation. Treatment with carnitine with or without diet was reported in 38 asymptomatic patients (26%).
Biochemical features of SBCAD deficiency
Available C5 concentrations at diagnosis were generally higher in symptomatic patients compared to asymptomatic patients, although not significantly different (median 1.2 and 0.76 μmol/L, respectively; p = 0.98). Two out of 162 patients (one symptomatic and one asymptomatic) were reported with C5 within the normal range (Tables 1 and 2 ). Overall, newborn screening allowed the diagnosis of 144 patients (89%). Data on 2MBG concentrations were scantily available; two asymptomatic subjects were reported with normal urinary excretion of 2MBG (Table 2) .
Longitudinal biochemical monitoring is available for the two newly reported patients with SBCAD deficiency (Figure 1) . In both patients, carnitine supplementation was followed by the reduction of blood C5 concentration; in particular, the second-born asymptomatic patient showed borderline blood C5 concentrations, whereas the patient previously suffering an acute metabolic decompensation showed steadily higher C5 concentrations while on treatment. Urinary excretion of 2MBG was elevated while on treatment. The two known variations c.512A>G and c.254G>A were not associated with SBCAD deficiency.
Molecular features of SBCAD deficiency
Discussion
SBCAD deficiency is an inborn error of isoleucine metabolism with uncertain clinical significance [15] . As this condition can be detected at expanded newborn screening through C5-carnitine elevation, having a picture of its potential clinical implications is essential to effectively inform parents of newly detected newborns.
Symptomatic SBCAD deficiency was reported in about 10% of identified patients so far. Neonatal-onset SBCAD deficiency is very rare and is commonly characterized by seizures and electroencephalography (EEG) abnormalities besides other non-specific clinical manifestations [1, 3, 6] . Epilepsy and developmental delay characterize the long-term follow-up of early-onset SBCAD deficiency. As valproyl-CoA can be a substrate of SBCAD, it is reasonable to avoid valproic acid for treating epilepsy in patients with SBCAD deficiency [2] . Later-onset clinical variants of SBCAD deficiency can manifest in infancy or childhood mostly with neurologic symptoms, including developmental delay, hypotonia, or autism. An additional potential clinical onset of SBCAD deficiency is represented by metabolic decompensation due to an intercurrent febrile illness, as observed in a newly diagnosed SBCADdeficient patient identified at our center. Interestingly, uncomplicated clinical course followed the resolution of the acute clinical symptoms. Although the actual impact of SBCAD deficiency in determining metabolic decompensation cannot be elucidated in the presented case (as gastroenteritis and severe dehydration can lead to metabolic acidosis and coma), these observations suggest that environmental stressors may trigger acute clinical manifestations of SBCAD deficiency, making it unsafe to consider this condition a "non-disease". Actually, a number of metabolic diseases share this behavior, including fatty acid oxidation disorders and organic acidemias [17, 18] . This supports a prudential management of asymptomatic patients with SBCAD deficiency, essentially based on carnitine supplementation besides the recommendation to avoid both fasting and protein overload. Furthermore, providing an emergency protocol for the management of intercurrent illnesses can be indicated in SBCAD deficiency. Hmong subjects represent a possible exception to these suggestions. In this population, indeed, SBCAD deficiency was shown to be highly prevalent (13.2/1000 births), almost invariably asymptomatic even on longterm follow-up, and due to homozygosity for the founder mutation c.1165A>G [7] . Mild hypotonia at 6 months of age, indeed, was reported only in one Hmong patient with these molecular findings [5] . This protective genotype was never described in non-Hmong patients.
At newborn screening, SBCAD should be considered as a differential diagnosis of C5-carnitine elevation, besides isovaleric acidemia and pivalic acid administration (present in some antibiotics). Newborn screening outcome in one newly reported patient confirmed the previous observation that SBCAD deficiency can present with near-normal C5-carnitine in newborns [6, 7] , subsequently confirmed by increased excretion of 2MBG detected by urine organic acids or acyl-glycine analyses. An oral bolus of 100 mg L-isoleucine/kg body weight may increase the sensitivity of organic acid analysis in detecting 2MBG. 2-ethylhydracrylic aciduria, an intermediate of the minor R-pathway of isoleucine degradation, was suggested as a subsidiary diagnostic marker of SBCAD deficiency [13] . Longitudinal biochemical monitoring of the two siblings with SBCAD deficiency showed consistent reduction of blood C5-carnitine concentration while on treatment with oral carnitine, although not reaching the normal concentration. The clinical significance of monitoring this parameter, however, is unclear due to the lack of published data.
SBCAD deficiency is transmitted as an autosomal recessive trait. Fifteen mutations in the ACADSB gene (11 exons, >20 kb) are known, including the new variant identified in the two siblings described in this study. Of them, 13 were associated with SBCAD deficiency. The c.1165A>G founder mutation in the Hmong population causes exon 10 skipping in the ACADSB gene. Exon skipping, indeed, is also implicated in the pathogenesis of other mutations in the ACADSB gene, namely c.1228G>A and c.303+3A>G [4, 11] . The former causes skipping of exon 10, whereas the latter induces missplicing through exon 3 skipping. As higher temperatures generally enhance skipping of exons [11, 19, 20] , it could be speculated that fever might further reduce SBCAD activity in the presence of such mutations. A tentative genotype-phenotype correlation in SBCAD revealed mutations largely associated with the asymptomatic course (c.1165A>G, c.38G>A, c.1159G>A, c.295C>T, c.50G>A, and c.621G>A), those mostly observed in symptomatic patients (c.303+3A>G, c.908G>C and c.1102T>C), and those non-predictive of the clinical course (c.763C>T, c.1228G>A, c.1145C>T, and c.443C>T). In particular, both the known and the new variants harbored by the two newly reported siblings belong to the latter group, consistently with their clinical course. Furthermore, although never observed in patients with SBCAD deficiency, two additional variations in the ACADSB gene (i.e. c.512A>G and c.254G>A) were reported as potential modifiers of systolic blood pressure in adults if associated with polymorphisms in the catecholamine-O-methyltransferase gene [21] .
In conclusion, the current data show that about 90% of patients with SBCAD deficiency are asymptomatic. In the Hmong population, SBCAD deficiency is likely benign. In the general population, the clinical course of SBCAD deficiency is poorly predictable. Consequently, clinical monitoring with special attention to situations that could stimulate metabolic decompensation is mandatory. It appears safe that non-Hmong patients identified at newborn screening with SBCAD deficiency receive carnitine supplementation, recommendation of avoiding prolonged fasting and protein overload, and an emergency protocol for the management of acute catabolic episodes. Furthermore, valproate is not indicated for the treatment of epilepsy in SBCAD deficiency. Longitudinal clinical and biochemical follow-up of symptomatic and asymptomatic patients with SBCAD deficiency is recommended.
